Results 11 to 20 of about 53,966 (229)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2

Biology, 2023
Sorafenib, a kinase inhibitor, has shown promising therapeutic efficacy in a subset of patients with acute myeloid leukemia (AML). However, despite its clinical effectiveness, sorafenib resistance is frequently observed in clinical settings, and the ...
Xi Xu, Weiwei Ma, Guo Qiu, Li Xuan, Chong He, Tian Zhang, Jian Wang, Qifa Liu   +7 more
doaj   +1 more source

Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study

Scientific Reports, 2021
Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) patients. This study aims to determine whether combining radiotherapy with sorafenib administration increases its efficacy.
Shou-Sheng Chu, Yu-Hsuan Kuo, Wen-Shan Liu, Shih-Chang Wang, Chung-Han Ho, Yi-Chen Chen, Ching-Chieh Yang, Hung-Chang Wu   +7 more
doaj   +1 more source

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma

Neoplasia: An International Journal for Oncology Research, 2014
Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC.
Jung-Chen Su, Ping-Hui Tseng, Szu-Hsien Wu, Cheng-Yi Hsu, Wei-Tien Tai, Yong-Shi Li, I-Ting Chen, Chun-Yu Liu, Kuen-Feng Chen, Chung-Wai Shiau   +9 more
doaj   +1 more source

Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular CarcinomaSummary

Cellular and Molecular Gastroenterology and Hepatology, 2020
Background & Aims: Sorafenib is a multireceptor tyrosine kinase inhibitor that can prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Although most HCC patients who receive sorafenib ultimately show disease progression,
Tomomi Hashiba, Taro Yamashita, Hikari Okada, Kouki Nio, Takehiro Hayashi, Yoshiro Asahina, Tomoyuki Hayashi, Takeshi Terashima, Noriho Iida, Hajime Takatori, Tetsuro Shimakami, Kazunori Kawaguchi, Kuniaki Arai, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Hiroyuki Takamura, Tetsuo Ohta, Masao Honda, Shuichi Kaneko   +19 more
doaj   +1 more source

Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3). [PDF]

PLoS ONE, 2014
Hand-foot skin reaction is a most common multi-kinase inhibitor-related adverse event. This study aimed to examine whether the toxicity of sorafenib and sunitinib for human keratinocytes was associated with inhibiting signal transduction and activator of
Kazuhiro Yamamoto, Atsushi Mizumoto, Kohji Nishimura, Atsushi Uda, Akira Mukai, Kazuhiko Yamashita, Manabu Kume, Hiroo Makimoto, Toshinori Bito, Chikako Nishigori, Tsutomu Nakagawa, Takeshi Hirano, Midori Hirai   +12 more
doaj   +1 more source

Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells

Non-Coding RNA, 2022
The multikinase inhibitor, sorafenib, is a first-line treatment for hepatocellular carcinoma (HCC), but its limited efficacy, drug resistance and toxicity are a concern.
Qingchun Lu, Mingyang Xin, Qian Guo, Brad S. Rothberg, Ana M. Gamero, Ling Yang   +5 more
doaj   +1 more source

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

BMC Cancer, 2017
Background Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear.
Fei-Xiang Wu, Jie Chen, Tao Bai, Shao-Liang Zhu, Tian-Bo Yang, Lu-Nan Qi, Ling Zou, Zi-Hui Li, Jia-Zhou Ye, Le-Qun Li   +9 more
doaj   +1 more source

BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. [PDF]

PLoS ONE, 2013
The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC).
Wei-Chien Huang, Yi-Ling Hsieh, Chao-Ming Hung, Pei-Hsuan Chien, Yu-Fong Chien, Lei-Chin Chen, Chih-Yen Tu, Chia-Hung Chen, Sheng-Chieh Hsu, Yueh-Ming Lin, Yun-Ju Chen   +10 more
doaj   +1 more source

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis

Frontiers in Pharmacology, 2022
Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib ...
Zhi-Yong Liu, Zhi-Yong Liu, Dan-Ying Zhang, Dan-Ying Zhang, Xia-Hui Lin, Xia-Hui Lin, Jia-Lei Sun, Jia-Lei Sun, Weinire Abuduwaili, Weinire Abuduwaili, Guang-Cong Zhang, Guang-Cong Zhang, Ru-Chen Xu, Ru-Chen Xu, Fu Wang, Fu Wang, Xiang-Nan Yu, Xiang-Nan Yu, Xuan Shi, Xuan Shi, Bin Deng, Ling Dong, Ling Dong, Shu-Qiang Weng, Shu-Qiang Weng, Ji-Min Zhu, Ji-Min Zhu, Xi-Zhong Shen, Xi-Zhong Shen, Xi-Zhong Shen, Tao-Tao Liu, Tao-Tao Liu   +31 more
doaj   +1 more source

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis

Journal of Experimental & Clinical Cancer Research, 2023
Background Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to explore
Yan Li, Wenjuan Yang, Yuanyuan Zheng, Weiqi Dai, Jie Ji, Liwei Wu, Ziqi Cheng, Jie Zhang, Jingjing Li, Xuanfu Xu, Jianye Wu, Mingwei Yang, Jiao Feng, Chuanyong Guo   +13 more
doaj   +1 more source